Boltwood Capital Management Grows Stake in GSK plc (NYSE:GSK)

Boltwood Capital Management boosted its stake in GSK plc (NYSE:GSK) by 9.9% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 12,453 shares of the pharmaceutical company’s stock after buying an additional 1,120 shares during the quarter. Boltwood Capital Management’s holdings in GSK were worth $421,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GSK. FMR LLC boosted its stake in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC boosted its stake in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC grew its holdings in shares of GSK by 14.3% during the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock worth $16,747,000 after buying an additional 51,378 shares in the last quarter. Cerity Partners LLC raised its position in shares of GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after buying an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC lifted its stake in shares of GSK by 20.0% in the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after buying an additional 83,433 shares in the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Trading Up 1.5 %

Shares of GSK stock traded up $0.49 during trading hours on Monday, hitting $33.96. The company’s stock had a trading volume of 1,396,024 shares, compared to its average volume of 2,055,944. The stock has a market cap of $70.38 billion, a price-to-earnings ratio of 22.05, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. GSK plc has a twelve month low of $32.83 and a twelve month high of $45.92. The firm has a fifty day moving average of $34.75 and a 200-day moving average of $38.40.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. The ex-dividend date of this dividend is Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.63%. GSK’s dividend payout ratio (DPR) is currently 98.70%.

Analysts Set New Price Targets

A number of research firms have weighed in on GSK. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Sunday. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.